Hep C Experts Condemn Cochrane Review Dissing Direct Antivirals

Earlier this month, a pooled analysis by the prestigious Cochrane Collaboration questioned whether sofosbuvir and other direct-acting antivirals (DAAs) can actually save lives in the long run -- a finding that could deal a massive blow to hepatitis C patients and drug companies alike. The problem is that it's simply not true, according to a chorus of experts who have called the Cochrane review "outdated," "fundamentally flawed," and "absurd." In an

The Week in Review: June 2 – June 9, 2017

Friday, June 9, 2017 News Recap Somebody Pinch Me This week saw the release of a report from the Cochrane Collaboration which concluded not only that DAAs were ineffective but that they might also be bad for you and not even cure HCV.  The news item was picked up by various media outlets and was hard to miss (No valid evidence $40,000 miracle drug cures hepatitis C – study).  Thankfully other researchers from around the world jumped in on this poor ...

Sofosbuvir Reduces Transplant Need and Mortality Rates in Hepatitis C Patients, Study Finds

Sofosbuvir (sold under the brand name Sovaldi from Gilead Sciences, among others) significantly reduces the risk of death and the need for liver transplant in patients with hepatitis C who suffer from advanced stages of liver disease. Researchers at Intermountain Healthcare’s Intermountain Medical Center in Salt Lake City studied almost 1,900 patients with hepatitis C and found that the number of patients needing a liver transplant was reduced by 40 per...